Answers are grounded in this paper and cite their sources.
Background: Type 2 diabetes mellitus (T2DM) involves impaired insulin secretion and insulin resistance. Zinc is crucial for insulin synthesis, storage, and secretion. This study evaluated zinc supplementation as an adjuvant to metformin for glycaemic control and metabolic parameters in patients with T2DM. Methods: A 12-month prospective, randomised, open-label, comparative study enrolled 100 adults with T2DM (HbA1c 6.5–8%) receiving stable metformin therapy. Participants were randomised to metformin monotherapy (Group A) or metformin plus zinc sulfate monohydrate 55 mg twice daily (Group B). A 3-month follow-up assessed FBG, PPBG, HbA1c, and lipid profiles. Results: Ninety-seven patients completed the study. Group B showed significant reductions in FBG (p = 0.048), PPBG (p = 0.047), and HbA1c (p = 0.026) compared with Group A. No significant changes were observed in BMI or lipid profiles. Mild adverse effects occurred in 16.49% of participants and were equally distributed between the groups. Conclusion: Adjuvant zinc supplementation significantly improves short-term glycaemic control in metformin-treated patients with T2DM without increasing adverse effects. Prophylactic zinc supplementation may be an effective adjunct for preventing hyperglycaemia.
No takes yet. Share an insight, caveat, or question.
C et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: